← Alle mensen

MB

Mauricio Burotto

11 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as Eerstelijns Therapy for Metastatic Nonsquamous NSCLC: Ph...
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-09
Health-related quality of life with belzutifan versus everolimus for gevorderd renal cell carcinoma (LITESPARK-005): ...
The Lancet. Oncology · 2025-04
Subcutaan versus IV atezolizumab: IMscin001 update
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024-10
Belzutifan versus everolimus bij gevorderd RCC: LITESPARK-005 fase III
The New England journal of medicine · 22 augustus 2024
Brigatinib versus alectinib bij ALK-positief NSCLC na crizotinib: ALTA-2 fase II
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2023-12
Nivolumab plus gemcitabine-cisplatine bij gevorderd urotheelcarcinoom: CheckMate 901 fase III
The New England journal of medicine · 9 november 2023
Cabozantinib plus nivolumab-ipilimumab bij niercelcarcinoom: COSMIC-313 definitief
The New England journal of medicine · 11 mei 2023
Nivolumab plus ipilimumab plus cabozantinib bij onbehandeld mRCC: COSMIC-313 fase III
European journal of cancer (Oxford, England : 1990) · 2022-12
Nivolumab-cabozantinib versus sunitinib bij mRCC: CheckMate 9ER langetermijn
The Lancet. Oncology · 2022-07
Voorkeur voor subcutane pertuzumab-trastuzumab: patiëntbeleving
European journal of cancer (Oxford, England : 1990) · 2021-07
Nivolumab plus cabozantinib versus sunitinib bij gevorderd RCC: CheckMate 9ER fase III
The New England journal of medicine · 4 maart 2021